Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial-Reference-Cited by-同舟云学术

Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial

Published:2016-07-06 Issue:12 Volume:36 Page:1783-1792
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Meissner Eric G.¹²³,McLaughlin Mary¹,Matthews Lindsay³,Gharib Ahmed M.⁴,Wood Bradford J.⁵,Levy Elliot⁵,Sinkus Ralph⁶,Virtaneva Kimmo⁷,Sturdevant Dan⁷,Martens Craig⁷,Porcella Stephen F.⁷,Goodman Zachary D.⁸,Kanwar Bittoo⁹,Myers Robert P.⁹,Subramanian Mani⁹,Hadigan Colleen¹,Masur Henry³,Kleiner David E.¹⁰,Heller Theo¹¹,Kottilil Shyam¹,Kovacs Joseph A.³,Morse Caryn G.³

Affiliation:

1. Laboratory of Immunoregulation; National Institute of Allergy and Infectious Diseases; Bethesda MD USA

2. Division of Infectious Diseases; Department of Microbiology and Immunology; Medical University of South Carolina; Charleston SC USA

3. Critical Care Medicine Department; AIDS Section; NIH Clinical Center; Bethesda MD USA

4. Biomedical and Metabolic Imaging Branch; National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda MD USA

5. Radiology and Imaging Sciences; NIH Clinical Center; Bethesda MD USA

6. Biomedical Engineering; Imaging Sciences and Biomedical Engineering Division; Kings College; London UK

7. Genomics Unit; Research Technology Section; Rocky Mountain Laboratories; National Institute of Allergy and Infectious Diseases; Hamilton MT USA

8. Center for Liver Diseases; Inova Fairfax Hospital; Falls Church VA USA

9. Gilead Sciences Inc.; Foster City CA USA

10. Laboratory of Pathology; National Cancer Institute; Bethesda MD USA

11. Liver Diseases Branch; National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda MD USA

Funder

National Institutes of Health

NIH Clinical Center

National Institute of Allergy and Infectious Diseases

National Institute of Diabetes and Digestive and Kidney Diseases

Office of AIDS Research

National Cancer Institute

Gilead Sciences

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.13177/fullpdf

Reference33 articles.

1. Pathogenesis of liver fibrosis;Hernandez-Gea;Ann Rev Pathol,2011

2. Therapy for fibrotic diseases: nearing the starting line;Friedman;Sci Transl Med,2013

3. Fibrosis-a common pathway to organ injury and failure;Rockey;N Engl J Med,2015

4. Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy;Labarga;J Viral Hepatitis,2014

5. Long term changes in liver histology following treatment of chronic hepatitis C virus;Shiffman;Ann Hepatol,2014

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Versatility of Collagen in Pharmacology: Targeting Collagen, Targeting with Collagen;International Journal of Molecular Sciences;2024-06-13

2. Non-invasive biomarkers prognostic of decompensation events in NASH cirrhosis: a systematic literature review;Journal of Molecular Medicine;2024-05-16

3. Crosstalk of lysyl oxidase-like 1 and lysyl oxidase prolongs their half-lives and regulates liver fibrosis through Notch signal;Hepatology Communications;2024-03-11

4. Exploring Extracellular Matrix Crosslinking as a Therapeutic Approach to Fibrosis;Cells;2024-03-02

5. Liver fibrosis: pathological features, clinical treatment and application of therapeutic nanoagents;Journal of Materials Chemistry B;2024